glp-1 cardiovascular outcomes 2025 news The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Results of cardiovascular outcomes trials

Semaglutide (Wegovy) has been granted FDA approval for the treatment of metabolic-associated steatohepatitis (MASH, or NASH with fibrosis)

This can reduce acute nausea without meaningfully affecting the medication pharmacokinetics

While lifestyle changes remain crucial, many people need extra support to achieve long-term weight loss

Alex Fishman, brand director at Pure Protein, added: As the dietary supplement market in the US becomes increasingly more congested and expensive, users and especially those taking GLP-1 medications are seeking simplified, yet effective solutions to help them achieve their health and fitness goals

Melatonin treatment also increased the number of oocytes collected, maturate oocytes, and good quality embryos